Hemogenyx Pharmaceuticals PLC (HEMO) - Cash Flow Conversion Efficiency

Latest as of December 2024: -2.090x

Based on the latest financial reports, Hemogenyx Pharmaceuticals PLC (HEMO) has a cash flow conversion efficiency ratio of -2.090x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.78 Million ≈ $-216.99 USD) by net assets (GBX853.49K ≈ $103.85 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Hemogenyx Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Hemogenyx Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read HEMO current and long-term liabilities for a breakdown of total debt and financial obligations.

Hemogenyx Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hemogenyx Pharmaceuticals PLC ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Imperial Ginseng Products Ltd V:IGP	0.105x
System1 Group PLC LSE:SYS1	-0.103x
BIORETEC OY F:0TN	N/A
Henderson Diversified Income Trust PLC LSE:HDIV	0.000x
Lendinvest PLC LSE:LINV	0.135x
Headlam Group LSE:HEAD	-0.163x
Angling Direct PLC LSE:ANG	0.121x
Sentient Brands Holdings Inc NASDAQ:SNBHD	0.019x

Annual Cash Flow Conversion Efficiency for Hemogenyx Pharmaceuticals PLC (2015–2024)

The table below shows the annual cash flow conversion efficiency of Hemogenyx Pharmaceuticals PLC from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Hemogenyx Pharmaceuticals PLC market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	GBX853.49K ≈ $103.85	GBX-4.12 Million ≈ $-500.91	-4.824x	-119.71%
2023-12-31	GBX2.78 Million ≈ $338.37	GBX-6.11 Million ≈ $-742.87	-2.195x	-144.66%
2022-12-31	GBX3.24 Million ≈ $394.64	GBX-2.91 Million ≈ $-354.14	-0.897x	-178.97%
2021-12-31	GBX8.17 Million ≈ $993.76	GBX-2.63 Million ≈ $-319.67	-0.322x	+84.34%
2020-12-31	GBX875.68K ≈ $106.55	GBX-1.80 Million ≈ $-218.81	-2.054x	-159.74%
2019-12-31	GBX-349.04K ≈ $-42.47	GBX-1.20 Million ≈ $-145.99	3.438x	+343.75%
2018-12-31	GBX959.17K ≈ $116.70	GBX-1.35 Million ≈ $-164.59	-1.410x	-563.74%
2017-12-31	GBX2.13 Million ≈ $259.39	GBX-452.98K ≈ $-55.11	-0.212x	+30.96%
2016-12-31	GBX903.71K ≈ $109.96	GBX-278.15K ≈ $-33.84	-0.308x	-30148.52%
2015-12-31	GBX77.82K ≈ $9.47	GBX79.71 ≈ $0.01	0.001x	--

About Hemogenyx Pharmaceuticals PLC

LSE:HEMO UK Biotechnology

Market Cap

$441.29K

GBX3.63 Billion GBX

Market Cap Rank

#30589 Global

#930 in UK

Share Price

GBX676.50

Change (1 day)

+0.22%

52-Week Range

GBX130.00 - GBX1545.00

All Time High

GBX1545.00